Economic Burden of the Out-of-Pocket Expenses for People with Multiple Sclerosis in France

Olivier Heinzlef, Guillaume Molinier, Benoît Hille (), Lise Radoszycki, Paul Dourgnon and Juliette Longin
Additional contact information
Olivier Heinzlef: Hôpital De Poissy
Guillaume Molinier: Ligue Française contre la Sclérose En Plaques (LFSEP)
Benoît Hille: Merck S.A.S.
Lise Radoszycki: Carenity
Paul Dourgnon: Institut de Recherche et Documentation en Economie de la Santé (IRDES)
Juliette Longin: Merck S.A.S.

PharmacoEconomics - Open, 2020, vol. 4, issue 4, No 5, 593-603

Abstract: Abstract Background People with chronic diseases in France frequently incur out-of-pocket expenses (OOPE) related to their medical care. Objective The objective of this study was to evaluate OOPE incurred by people with multiple sclerosis (MS) with respect to direct non-medical and medical expenditure. Methods Data were collected through a web-based survey using an online patient community platform (Carenity). The survey questionnaire contained 87 questions (numerical response or Likert scale) and took less than 30 min to complete. Participants rated their disability on a ten-point scale. Results In total, 376 patients, with a mean age of 48.3 years (95% confidence interval [CI] 47.2–49.5), participated in the survey. Participants estimated that they spent an average of €127 each month on OOPE for their MS, principally on physician consultations (mean annual expenditure of €75 by 183 participants), non-physician consultations (€358 by 135 participants) and non-prescription medication (mean expense of €67 per pharmacy visit by 234 patients). In total, 77% of participants who needed adaptations to their home or vehicle because of their MS contributed to the cost. No obvious relationship between OOPE and self-rated disability was observed. A total of 61.4% of participants reported that they had to choose between spending money on MS care or on their family and social life. Conclusions Most patients with MS incurred significant OOPE linked to consultations, non-prescription medications or home equipment and medical equipment. These outlays could lead to dilemmas when choosing between spending on MS care or family or social life.

Date: 2020
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-020-00199-7 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:4:y:2020:i:4:d:10.1007_s41669-020-00199-7

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-020-00199-7

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().